Apollo Therapeutics, a unique collaboration between UCL, Imperial College London and the University of Cambridge, and three global pharmaceutical companies, has attracted a further £226.5m of investment to translate scientific advances for patient benefit.
UCL partner Apollo Therapeutics receives $226.5M to translate medical research into treatments
